If you didn't find what you were looking for, try a new search!
Hosted by the AASM International Assembly Dr. Miglis and Dr. Plazzi, leading professionals with deep expertise in narcolepsy, will be offering unique insights and direct interaction opportunities. The webinar will provide specialized knowledge on the latest research, diagnosis, and treatment strategies specifically for [...]
On June 24, 2024, Harmony Biosciences announced FDA approval of its supplemental new drug application (sNDA) for pitolisant (WAKIX) tablets for the treatment of excessive daytime sleepiness (EDS) in pediatric patients aged 6 and older with narcolepsy. About pitolisant (WAKIX) Pitolisant is a [...]
The American Academy of Sleep Medicine (AASM) is seeking public comments on the proposed revisions to the narcolepsy quality measure set, originally published in 2015, which is currently undergoing measure maintenance. The public comment period will be open for 30 days, beginning June 12, [...]
Harmony Biosciences | IEP Gold Level Sponsor Know Narcolepsy is an online resource that seeks to help healthcare professionals by offering information about the neurobiology of sleep and wakefulness and the pathophysiology of narcolepsy, as well as providing tools and resources for their practice. [...]
The AASM Payer Policy Review Committee (PPRC) has received several member inquiries regarding denials for prescribing concomitant medications for the treatment of narcolepsy. Following review of several payers’ pharmaceutical policies and a meeting with a payer representative, it is clear that payers have a [...]
Lindsay McCullough, MD Most people are surprised to hear that I have narcolepsy. An invisible diagnosis, narcolepsy causes many to struggle to cope with the symptoms without knowing they have the condition. Others walk in silence for fear of being judged. In hindsight, [...]
Save the date for the third annual World Narcolepsy Day on Wednesday, Sept. 22, 2021! Led by 27 patient advocacy organizations across 6 continents, World Narcolepsy Day unites the international narcolepsy community to inspire action, increase public knowledge, and elevate the voices of [...]
On July 28, 2021, Takeda Pharmaceutical Company announced the FDA granted Breakthrough Therapy designation to TAK-994, which may provide a future treatment option targeting the orexin deficiency underlying narcolepsy type 1. About TAK-994 TAK-994 is a Phase 2 investigational oral orexin agonist designed to [...]
Harmony Biosciences announced on Oct. 13, 2020, that the U.S. Food and Drug Administration has approved Wakix (pitolisant) for the treatment of cataplexy in adult patients with narcolepsy. The FDA previously approved Wakix for the treatment of excessive daytime sleepiness in adult patients with [...]
Luis Ortiz, MD, is a sleep physician in the Sleep Center at Johns Hopkins All Children’s Hospital in St. Petersburg, Florida. Diagnosed with narcolepsy type 1 as a young adult, Dr. Ortiz is an advocate for the early diagnosis and treatment of narcolepsy, increased [...]
Jazz Pharmaceuticals announced July 22, 2020, that the U.S. Food and Drug Administration has approved the Xywav oral solution for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy who are 7 years of age and older. Multiple Xywav dosing options [...]
Harmony Biosciences announced Aug. 15, 2019, that the U.S. Food and Drug Administration has approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Harmony states that Wakix is the only treatment approved for patients with narcolepsy that is not [...]
On Aug. 9, 2019, a new feature film, "Ode to Joy," opened in select theaters and released via video on demand across the United States. "Ode to Joy" is a romantic comedy about a man, Charlie (played by Martin Freeman), navigating romance while living [...]
AASM member Brenda Moore, RPSGT, a sleep technologist at the Research Medical Center Brookside Campus Sleep Disorders Center in Kansas City, Missouri, describes her dreamlike journey into the sleep field. I struggled during my childhood with an endless need [...]
The Wisconsin Physicians Service Insurance Corporation (WPS) has issued a new local coverage determination (LCD) policy (L37003) that provides new coverage information related to narcolepsy testing.
Most people with narcolepsy report receiving a diagnosis more than 1 year after symptom onset, according to a study in the March issue of the Journal of Clinical Sleep Medicine.
A new study in the December 15 issue of the Journal of Clinical Sleep Medicine suggests that narcolepsy type 1 is associated with obesity and precocious puberty when appearing at a young age.
A study in the March issue of the Journal of Clinical Sleep Medicine suggests that a narcolepsy diagnosis is associated with a serious and costly impact on a range of patient outcomes.
A study of narcolepsy patients who were taking sodium oxybate for treatment of excessive daytime sleepiness and cataplexy found that a clinically meaningful therapeutic response was achieved in the majority of patients within one to two months.
According to a study in the February issue of the Journal of Clinical Sleep Medicine, 10 percent of adolescents who displayed excessive daytime sleepiness indicative of narcolepsy screened positive for marijuana.
In collaboration with patient advocacy groups, Honda Motor Co., Ltd., has produced new public service announcements encouraging people with narcolepsy symptoms to talk to a sleep specialist for help. The PSAs will debut this weekend, including a broadcast Friday evening, Nov. 7, on HGTV.
The Narcolepsy Network, the advocacy group for patients with narcolepsy, is hosting their 29th annual conference Oct. 17-19 at the Hyatt Regency Denver Tech Center. The annual conference brings together people whose lives are affected by narcolepsy to share their experiences with one another. The meeting also features presentations by narcolepsy researchers and sleep physicians. For more information about the upcoming meeting, visit the Narcolepsy Network website.
The Narcolepsy Network, an advocacy group for narcolepsy patients, is hosting an event on April 26 to further its mission of promoting research and awareness of the sleep disorder.
A study in the March issue of SLEEP is the first to identify increased mortality in narcolepsy. Results show that narcolepsy is associated with approximately 1.5-fold excess mortality relative to those without narcolepsy.
People with narcolepsy may confuse dreams with reality A brief report in the February issue of the journal SLEEP suggests that it may be common for people with narcolepsy to mistake the memory of a dream for a real experience.
A study of 109 consecutive patients with newly diagnosed narcolepsy reports that patients were delayed in their diagnosis by a median of 8 years.
A study in the January issue of SLEEP found that participants with the human leukocyte antigen (HLA) allele DQB1*06:02 were 251 times more likely to have narcolepsy with cataplexy than participants without the common gene variant, which had a remarkably high negative predictive value of 99.32 percent.
A new study conducted across Europe found an extraordinary association between narcolepsy and a specific gene variant related to the immune system.
A new literature review describes a consistent characterization of fragmented nighttime sleep in patients with narcolepsy.
In April the Food and Drug Administration announced that narcolepsy was selected as one of the disease areas to be addressed during the first three years of its Patient-Focused Drug Development initiative. Last week the FDA announced that it will hold a public meeting to gather patient and patient stakeholder input on how narcolepsy impacts daily life and on current approaches to treating narcolepsy.
A new study provides surprising evidence that people with narcolepsy have an increased number of neurons that produce histamine, suggesting that histamine signaling may be a novel therapeutic target for this potentially disabling sleep disorder.
In a statement published in the Federal Register on April 11, the Food and Drug Administration announced that narcolepsy was selected as one of the disease areas to be addressed during the first three years of Patient-Focused Drug Development.